Hypothesis

Acute senescent cells release exosomes enriched in IGFBP4/7, miR-143/222 and pro‑angiogenic integrins that transiently stabilize endothelial HIF‑1α and drive reparative angiogenesis; sustained oxidative stress reprograms exosome loading toward SASP proteases and senescence‑propagating miRNAs, converting the same secretory program from tissue‑restorative to pathological. Consequently, senolytic drugs administered before the exosome cargo shift abolish beneficial regenerative signaling, whereas delayed senolysis after the shift removes the harmful exosome pool while sparing early pro‑repair vesicles.

Mechanistic Rationale

Senescent exosomes are not a uniform cargo; their sorting depends on the redox state of the donor cell via the nSMase2‑Rab27a axis. Transient ROS spikes after injury activate nSMase2, favoring loading of miR-143/222 and IGFBP7 into exosomes that engage endothelial αvβ3 integrins, inhibit PTEN, and amplify HIF‑1α‑mediated VEGF signaling (5). Persistent ROS, characteristic of chronic senescence, shifts nSMase2 activity toward sorting of inflammatory SASP components (SERPINC1, F2, F5, PLG) and senescence‑propagating miRNAs (miR-483-5p, miR-532-3p, miR-409-3p) (2). This biphasic loading explains why early senescent exosomes support wound healing and stem‑cell niche maintenance (1), while later exosomes propagate senescence to neighboring cells via IGFBP4/7‑mediated paracrine induction (3).

Testable Predictions

1. In a murine myocardial infarction model, exosome isolates collected 6‑12 h post‑MI will contain higher miR-143/222 and IGFBP7 and will enhance endothelial tube formation in vitro; isolates from 4‑7 days post‑MI will be enriched in SASP proteases and will induce senescence in naïve fibroblasts.
2. Pharmacologic inhibition of nSMase2 (using GW4869) administered 24 h after MI will block the later pathogenic exosome burst without reducing the early pro‑angiogenic exosome peak, resulting in improved ejection fraction and reduced fibrosis compared with vehicle.
3. Administering a senolytic (e.g., navitoclax) before 12 h post‑MI will diminish the early regenerative exosome surge, leading to larger infarct scars and worsened function; the same senolytic given after 48 h will limit scar expansion by clearing chronically senescent cells.

Experimental Approach

• Exosome profiling: Collect plasma and cardiac interstitial fluid at 6 h, 24 h, 72 h, and 7 days post‑MI; perform NTA, western blot for CD63/IGFBP7/miR-143-3p, and protease activity assays.
• Functional assays: Treat human umbilical vein endothelial cells (HUVECs) with timed exosomes; measure HIF‑1α stabilization (Western), tube formation (Matrigel), and senescence (SA‑β‑gal).
• In vivo intervention: Randomize mice to receive GW4869 or navitoclax at defined intervals; assess cardiac function by echocardiography, fibrosis by Masson’s trichrome, and senescent cell burden by p16^INK4a immunostaining.
• Controls: Include sham‑operated, vehicle‑treated, and exosome‑depleted (ultracentrifugation) groups.

Potential Outcomes and Falsifiability

If early exosomes are pro‑regenerative and later exosomes pathogenic, then:

• Early exosome supplementation should rescue angiogenesis in nSMase2‑inhibited mice; failure to do so would refute the cargo‑switch mechanism.
• Delayed senolysis improving function without affecting early exosome levels would support the hypothesis; lack of benefit or worsened outcome would falsify the timing premise.
• Demonstrating that ROS modulation alters exosome miRNA/protease ratios in donor senescent cells would directly link redox state to cargo sorting.

This hypothesis reframes senolytics not as blunt eliminators but as timed modulators of a dynamic exosome‑mediated repair‑to‑damage switch, offering a mechanistic route to preserve tissue‑regenerative signals while curbing chronic senescence spread.